Pharming's Joenja Receives EU Marketing Authorization for APDS, First Treatment in Europe

summarizeSummary

Pharming Group N.V. announced that the European Commission has granted marketing authorization for Joenja (leniolisib), making it the first approved treatment for APDS in the European Union.

check_boxKey Events

• EU Marketing Authorization Granted

  The European Commission has granted marketing authorization for Joenja® (leniolisib) for the treatment of Activated PI3K delta Syndrome (APDS) in adult and pediatric patients aged 12 years and older.

• First Approved Treatment in EU

  Joenja is now the first and only approved treatment for APDS in the European Union, addressing a significant unmet medical need for patients with this rare primary immunodeficiency.

• European Launch Expected Q3 2026

  The first European launch of Joenja is anticipated in Germany in Q3 2026, with further launches across the EU pending national reimbursement negotiations.

• Global Expansion Continues

  This approval expands Joenja's market presence, adding to existing authorizations in the United States, United Kingdom, Japan, Australia, and Israel, reinforcing Pharming's global strategy.

auto_awesomeAnalysis

This final marketing authorization from the European Commission for Joenja (leniolisib) is a critical milestone for Pharming, opening up the significant European market for its rare disease drug. As the first approved treatment for Activated PI3K delta Syndrome (APDS) in the EU, it addresses a high unmet medical need and is expected to drive substantial revenue growth, with the first launch anticipated in Germany in Q3 2026.